373 related articles for article (PubMed ID: 15723623)
1. Matrix metalloproteinase inhibitors: a review on pharmacophore mapping and (Q)SARs results.
Kontogiorgis CA; Papaioannou P; Hadjipavlou-Litina DJ
Curr Med Chem; 2005; 12(3):339-55. PubMed ID: 15723623
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and evaluation of matrix metalloprotease inhibitors bearing cyclopropane-derived peptidomimetics as P1' and P2' replacements.
Reichelt A; Gaul C; Frey RR; Kennedy A; Martin SF
J Org Chem; 2002 Jun; 67(12):4062-75. PubMed ID: 12054939
[TBL] [Abstract][Full Text] [Related]
3. X-ray structures of human neutrophil collagenase complexed with peptide hydroxamate and peptide thiol inhibitors. Implications for substrate binding and rational drug design.
Grams F; Reinemer P; Powers JC; Kleine T; Pieper M; Tschesche H; Huber R; Bode W
Eur J Biochem; 1995 Mar; 228(3):830-41. PubMed ID: 7737183
[TBL] [Abstract][Full Text] [Related]
4. Molecular docking studies of a group of hydroxamate inhibitors with gelatinase-A by molecular dynamics.
Hou T; Zhang W; Xu X
J Comput Aided Mol Des; 2002 Jan; 16(1):27-41. PubMed ID: 12197664
[TBL] [Abstract][Full Text] [Related]
5. Affinity and selectivity of matrix metalloproteinase inhibitors: a chemometrical study from the perspective of ligands and proteins.
Matter H; Schwab W
J Med Chem; 1999 Nov; 42(22):4506-23. PubMed ID: 10579815
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of enzyme activity of and cell-mediated substrate cleavage by membrane type 1 matrix metalloproteinase by newly developed mercaptosulphide inhibitors.
Hurst DR; Schwartz MA; Jin Y; Ghaffari MA; Kozarekar P; Cao J; Sang QX
Biochem J; 2005 Dec; 392(Pt 3):527-36. PubMed ID: 16026329
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.
Yamamoto M; Tsujishita H; Hori N; Ohishi Y; Inoue S; Ikeda S; Okada Y
J Med Chem; 1998 Apr; 41(8):1209-17. PubMed ID: 9548812
[TBL] [Abstract][Full Text] [Related]
8. The intermediate S1' pocket of the endometase/matrilysin-2 active site revealed by enzyme inhibition kinetic studies, protein sequence analyses, and homology modeling.
Park HI; Jin Y; Hurst DR; Monroe CA; Lee S; Schwartz MA; Sang QX
J Biol Chem; 2003 Dec; 278(51):51646-53. PubMed ID: 14532275
[TBL] [Abstract][Full Text] [Related]
9. Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.
Scozzafava A; Supuran CT
J Med Chem; 2000 Oct; 43(20):3677-87. PubMed ID: 11020282
[TBL] [Abstract][Full Text] [Related]
10. Selective matrix metalloproteinase inhibitors for cancer.
Lia NG; Shib ZH; Tang YP; Duan JA
Curr Med Chem; 2009; 16(29):3805-27. PubMed ID: 19747139
[TBL] [Abstract][Full Text] [Related]
11. Potent inhibitors precise to S1' loop of MMP-13, a crucial target for osteoarthritis.
Kalva S; Saranyah K; Suganya PR; Nisha M; Saleena LM
J Mol Graph Model; 2013 Jul; 44():297-310. PubMed ID: 23938376
[TBL] [Abstract][Full Text] [Related]
12. A comparative QSAR study on carbonic anhydrase and matrix metalloproteinase inhibition by sulfonylated amino acid hydroxamates.
Gupta SP; Maheswaran V; Pande V; Kumar D
J Enzyme Inhib Med Chem; 2003 Feb; 18(1):7-13. PubMed ID: 12751815
[TBL] [Abstract][Full Text] [Related]
13. Crystal structure of human macrophage elastase (MMP-12) in complex with a hydroxamic acid inhibitor.
Nar H; Werle K; Bauer MM; Dollinger H; Jung B
J Mol Biol; 2001 Sep; 312(4):743-51. PubMed ID: 11575929
[TBL] [Abstract][Full Text] [Related]
14. N-O-isopropyl sulfonamido-based hydroxamates: kinetic characterisation of a series of MMP-12/MMP-13 dual target inhibitors.
Santamaria S; Nuti E; Cercignani G; Marinelli L; La Pietra V; Novellino E; Rossello A
Biochem Pharmacol; 2012 Sep; 84(6):813-20. PubMed ID: 22771631
[TBL] [Abstract][Full Text] [Related]
15. Tetrahydroisoquinoline-3-carboxylate based matrix-metalloproteinase inhibitors: design, synthesis and structure-activity relationship.
Matter H; Schudok M; Schwab W; Thorwart W; Barbier D; Billen G; Haase B; Neises B; Weithmann K; Wollmann T
Bioorg Med Chem; 2002 Nov; 10(11):3529-44. PubMed ID: 12213468
[TBL] [Abstract][Full Text] [Related]
16. Active site specificity profiling of the matrix metalloproteinase family: Proteomic identification of 4300 cleavage sites by nine MMPs explored with structural and synthetic peptide cleavage analyses.
Eckhard U; Huesgen PF; Schilling O; Bellac CL; Butler GS; Cox JH; Dufour A; Goebeler V; Kappelhoff R; Keller UAD; Klein T; Lange PF; Marino G; Morrison CJ; Prudova A; Rodriguez D; Starr AE; Wang Y; Overall CM
Matrix Biol; 2016 Jan; 49():37-60. PubMed ID: 26407638
[TBL] [Abstract][Full Text] [Related]
17. Structure-based design of TACE selective inhibitors: manipulations in the S1'-S3' pocket.
Huang A; Joseph-McCarthy D; Lovering F; Sun L; Wang W; Xu W; Zhu Y; Cui J; Zhang Y; Levin JI
Bioorg Med Chem; 2007 Sep; 15(18):6170-81. PubMed ID: 17606376
[TBL] [Abstract][Full Text] [Related]
18. Peptide substrate specificities and protein cleavage sites of human endometase/matrilysin-2/matrix metalloproteinase-26.
Park HI; Turk BE; Gerkema FE; Cantley LC; Sang QX
J Biol Chem; 2002 Sep; 277(38):35168-75. PubMed ID: 12119297
[TBL] [Abstract][Full Text] [Related]
19. A quantitative structure-activity relationship study of hydroxamate matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines.
Gupta SP; Kumar D; Kumaran S
Bioorg Med Chem; 2003 May; 11(9):1975-81. PubMed ID: 12670648
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in studies on hydroxamates as matrix metalloproteinase inhibitors: a review.
Yadav RK; Gupta SP; Sharma PK; Patil VM
Curr Med Chem; 2011; 18(11):1704-22. PubMed ID: 21428880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
